alexa Personalized Medicine And Hepatitis C
ISSN: 2153-0645

Journal of Pharmacogenomics & Pharmacoproteomics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

2nd International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics
November 03-05, 2014 Embassy Suites Las Vegas, USA

Jo?o Renato Rebello Pinho
Accepted Abstracts: J Pharmacogenomics Pharmacoproteomics
DOI: 10.4172/2153-0645.S1.004
Hepatitis C Virus (HCV) is responsible for one of the most important viral pandemics infecting more than 170 million individuals around the world with a relevant link to severe chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Treatment of this infection was until recently based on a combined therapy using Pegylated Interferon and Ribavirin (RBV) for different time frames depending on the infecting viral genotype and to the response during treatment. In the last five years, there has been an increase in the understanding of the interactions among human genes and HCV infection. Another important progress was the introduction of viral protease, NS5A and polymerase inhibitors that largely increased the treatment response for this disease. It was also recently determined that some SNPs in the Inosine Triphosphatase (ITPA) gene also influence the anemia induced by RBV and some of this new drugs. A strong association between two SNPs near the Interleukin 28B (IL28B) or Interferon λ 3 (IFNL3) gene was found with spontaneous HCV clearance and response to treatment. More recently, another polymorphism in the same region was found, leading to a frame shift that inactivates Interferon λ 4 (IFNL4), while the ΔG allele results in translation of IFNL4 protein that might be associated with a poor prognosis for the treatment. To improve the follow up of hepatitis C patients, particularly to increase response rates and decrease treatment side effects, the use of molecular markers to characterize the virus and the human polymorphisms cited above are increasing.
Jo?o Renato Rebello Pinho graduated in Medicine (1984) and got his PhD in Biochemistry at the University of S?o Paulo (1995). He had held internships in France and the United States and worked in Adolfo Lutz Institute, Institute of Tropical Medicine, Foundation Pr?-Sangue of S?o Paulo and Laborat?rio Bioqu?mico Jardim Paulista. Currently, he is Medical Coordinator at Laboratory of Special Techniques (Molecular Biology, Genetics and HLA) at Albert Einstein Diagnostic Medicine and is responsible for the Laboratory of Tropical Gastroenterology and Hepatology, Institute of Tropical Medicine, Department of Gastroenterology, School of Medicine, University of S?o Paulo.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version